Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 02-May-24 9:07 PM View:  | Young Jonathan Chief Operating Officer | Akero Therapeutics, Inc. (AKRO) | 01-May-24 | Market Sale (Planned) | 5,000 | $20.15 | $100,750.00 | (2%) 323.31K to 318.31K | 2% |
| 03-Apr-24 6:55 PM View: | Young Jonathan Chief Operating Officer | Akero Therapeutics, Inc. (AKRO) | 01-Apr-24 | Private Sale (Planned) | 5,000 | $24.38 | $121,913.00 | (< 1%) 592.01K to 587.01K | |
| 15-Mar-24 4:42 PM View: | Young Jonathan Chief Operating Officer | Akero Therapeutics, Inc. (AKRO) | 13-Mar-24 | Private Sale | 651 | $28.33 | $18,442.80 | (< 1%) 328.96K to 328.31K | |
| 15-Mar-24 4:42 PM View: | Rolph Timothy Chief Scientific Officer | Akero Therapeutics, Inc. (AKRO) | 13-Mar-24 | Private Sale | 619 | $28.33 | $17,536.30 | (< 1%) 183.18K to 182.56K | |
| 15-Mar-24 4:45 PM View: | Yale Catriona Chief Development Officer | Akero Therapeutics, Inc. (AKRO) | 13-Mar-24 | Private Sale | 723 | $28.33 | $20,482.60 | (< 1%) 78.42K to 77.69K | |
| 15-Mar-24 4:43 PM View: | Cheng Andrew President and CEO Director | Akero Therapeutics, Inc. (AKRO) | 13-Mar-24 | Private Sale | 1,969 | $28.33 | $55,781.80 | (< 1%) 591.42K to 589.45K | |
| 15-Mar-24 4:44 PM View: | White William Richard Chief Financial Officer | Akero Therapeutics, Inc. (AKRO) | 13-Mar-24 | Private Sale | 724 | $28.33 | $20,510.90 | (1%) 50.35K to 49.63K | |
| 06-Mar-24 10:00 PM View: | Cheng Andrew President and CEO Director | Akero Therapeutics, Inc. (AKRO) | 04-Mar-24 | Option Exercise | 75,000 | $17.17 | $1,288,060.00 | 13% 591.42K to 666.42K | |
| 06-Mar-24 10:00 PM View: | Yale Catriona Chief Development Officer | Akero Therapeutics, Inc. (AKRO) | 04-Mar-24 | Planned Option Sale | 20,646 | $35.49 | $732,727.00 | (21%) 99.06K to 78.42K | |
| 06-Mar-24 10:00 PM View: | Cheng Andrew President and CEO Director | Akero Therapeutics, Inc. (AKRO) | 04-Mar-24 | Planned Option Sale | 75,000 | $32.87 | $2,465,060.00 | (11%) 666.42K to 591.42K | |
| 06-Mar-24 10:00 PM View: | Yale Catriona Chief Development Officer | Akero Therapeutics, Inc. (AKRO) | 04-Mar-24 | Option Exercise | 20,646 | $13.96 | $288,124.00 | 26% 78.42K to 99.06K | |
| 05-Mar-24 5:16 PM View: | Young Jonathan Chief Operating Officer | Akero Therapeutics, Inc. (AKRO) | 01-Mar-24 | Option Exercise | 83,321 | $0.62 | $51,242.40 | 34% 245.64K to 328.96K | |
| 03-Jan-24 5:00 PM View: | Cheng Andrew President and CEO Director | Akero Therapeutics, Inc. (AKRO) | 02-Jan-24 | Option Exercise | 40,000 | $0.62 | $24,600.00 | 7% 550.91K to 590.91K | |
| 29-Dec-23 8:30 PM View: | Young Jonathan Chief Operating Officer | Akero Therapeutics, Inc. (AKRO) | 27-Dec-23 | Option Exercise | 5,414 | $6.36 | $34,433.00 | 2% 245.13K to 250.54K | |
| 29-Dec-23 8:30 PM View: | Young Jonathan Chief Operating Officer | Akero Therapeutics, Inc. (AKRO) | 27-Dec-23 | Option Sale | 5,414 | $24.00 | $129,936.00 | (2%) 250.54K to 245.13K | |
| 18-Dec-23 8:39 PM View: | Young Jonathan Chief Operating Officer | Akero Therapeutics, Inc. (AKRO) | 14-Dec-23 | Market Sale | 543 | $20.76 | $11,272.70 | (< 1%) 245.67K to 245.13K | 5% |
| 18-Dec-23 8:40 PM View: | White William Richard Chief Financial Officer | Akero Therapeutics, Inc. (AKRO) | 14-Dec-23 | Market Sale | 611 | $20.76 | $12,684.40 | (1%) 50.97K to 50.35K | 5% |
| 18-Dec-23 8:49 PM View: | Yale Catriona Chief Development Officer | Akero Therapeutics, Inc. (AKRO) | 14-Dec-23 | Market Sale | 597 | $20.76 | $12,393.70 | (< 1%) 78.51K to 77.91K | 5% |
| 18-Dec-23 8:37 PM View: | Cheng Andrew President and CEO Director | Akero Therapeutics, Inc. (AKRO) | 14-Dec-23 | Market Sale | 1,628 | $20.76 | $33,797.30 | (< 1%) 552.54K to 550.91K | 5% |
| 18-Dec-23 8:29 PM View: | Rolph Timothy Chief Scientific Officer | Akero Therapeutics, Inc. (AKRO) | 14-Dec-23 | Market Sale | 514 | $20.76 | $10,670.60 | (< 1%) 183.19K to 182.67K | 5% |
| 11-Dec-23 10:00 PM View: | Cheng Andrew President and CEO Director | Akero Therapeutics, Inc. (AKRO) | 11-Dec-23 | Planned Option Sale | 7,405 | $20.02 | $148,273.00 | (1%) 559.94K to 552.54K | |
| 11-Dec-23 10:00 PM View: | Cheng Andrew President and CEO Director | Akero Therapeutics, Inc. (AKRO) | 11-Dec-23 | Option Exercise | 7,405 | $6.36 | $47,095.80 | 1% 552.54K to 559.94K | |
| 12-Dec-23 4:43 PM View: | Young Jonathan Chief Operating Officer | Akero Therapeutics, Inc. (AKRO) | 08-Dec-23 | Grant | 32,497 | -- | -- | 15% 213.18K to 245.67K | |
| 11-Dec-23 10:00 PM View: | Cheng Andrew President and CEO Director | Akero Therapeutics, Inc. (AKRO) | 08-Dec-23 | Planned Option Sale | 12,873 | $20.01 | $257,571.00 | (2%) 565.41K to 552.54K | |
| 12-Dec-23 4:43 PM View: | White William Richard Chief Financial Officer | Akero Therapeutics, Inc. (AKRO) | 08-Dec-23 | Grant | 32,497 | -- | -- | 176% 18.47K to 50.97K | |
| 12-Dec-23 4:26 PM View: | Yale Catriona Chief Development Officer | Akero Therapeutics, Inc. (AKRO) | 08-Dec-23 | Grant | 32,497 | -- | -- | 71% 46.01K to 78.51K | |
| 12-Dec-23 4:38 PM View: | Rolph Timothy Chief Scientific Officer | Akero Therapeutics, Inc. (AKRO) | 08-Dec-23 | Grant | 32,497 | -- | -- | 22% 150.69K to 183.19K | |
| 11-Dec-23 10:00 PM View: | Cheng Andrew President and CEO Director | Akero Therapeutics, Inc. (AKRO) | 08-Dec-23 | Option Exercise | 12,873 | $6.36 | $81,872.30 | 2% 552.54K to 565.41K | |
| 12-Dec-23 4:35 PM View: | Lamy Patrick See Remarks | Akero Therapeutics, Inc. (AKRO) | 08-Dec-23 | Grant | 18,570 | -- | -- | 100% 0 to 18.57K | |
| 11-Dec-23 10:00 PM View: | Cheng Andrew President and CEO Director | Akero Therapeutics, Inc. (AKRO) | 08-Dec-23 | Grant | 91,541 | -- | -- | 20% 461.0K to 552.54K | |
| 11-Dec-23 10:00 PM View: | Graham G. Walmsley Director | Akero Therapeutics, Inc. (AKRO) | 08-Dec-23 | Market Purchase | 100,000 | $19.83 | $1,982,940.00 | 14% 702.17K to 802.17K | (< 1%) |
| 11-Dec-23 10:00 PM View: | Cheng Andrew President and CEO Director | Akero Therapeutics, Inc. (AKRO) | 07-Dec-23 | Option Exercise | 6,700 | $6.36 | $42,612.00 | 1% 461.0K to 467.7K | |
| 11-Dec-23 10:00 PM View: | Cheng Andrew President and CEO Director | Akero Therapeutics, Inc. (AKRO) | 07-Dec-23 | Planned Option Sale | 6,700 | $20.02 | $134,125.00 | (1%) 467.7K to 461.0K | |
| 05-Dec-23 8:37 AM View: | Graham G. Walmsley Director | Akero Therapeutics, Inc. (AKRO) | 01-Dec-23 | Purchase | 50,000 | $16.99 | $849,730.00 | 8% 652.17K to 702.17K | |
| 05-Dec-23 8:37 AM View: | Graham G. Walmsley Director | Akero Therapeutics, Inc. (AKRO) | 30-Nov-23 | Private Purchase | 50,000 | $16.90 | $844,835.00 | 8% 602.17K to 652.17K | |
| 21-Nov-23 5:30 PM View: | Young Jonathan Chief Operating Officer | Akero Therapeutics, Inc. (AKRO) | 17-Nov-23 | Sale | 30,000 | $14.68 | $440,259.00 | (12%) 243.18K to 213.18K | |
| 04-Oct-23 8:41 PM View: | Cheng Andrew President and CEO Director | Akero Therapeutics, Inc. (AKRO) | 02-Oct-23 | Planned Option Sale | 25,000 | $47.91 | $1,197,830.00 | (5%) 486.0K to 461.0K | |
| 04-Oct-23 8:33 PM View: | Young Jonathan Chief Operating Officer | Akero Therapeutics, Inc. (AKRO) | 02-Oct-23 | Option Exercise | 490 | $21.10 | $10,339.00 | < 1% 243.18K to 243.67K | (7%) |
| 04-Oct-23 8:33 PM View: | Young Jonathan Chief Operating Officer | Akero Therapeutics, Inc. (AKRO) | 02-Oct-23 | Planned Private Option Sale | 490 | $51.10 | $25,039.00 | (< 1%) 243.67K to 243.18K | |
| 04-Oct-23 8:41 PM View: | Cheng Andrew President and CEO Director | Akero Therapeutics, Inc. (AKRO) | 02-Oct-23 | Option Exercise | 25,000 | $6.36 | $159,000.00 | 5% 461.0K to 486.0K | |
| 25-Sep-23 8:31 PM View: | Yale Catriona Chief Development Officer | Akero Therapeutics, Inc. (AKRO) | 21-Sep-23 | Option Exercise | 5,000 | $6.36 | $31,800.00 | 11% 46.01K to 51.01K | |
| 25-Sep-23 8:31 PM View: | Yale Catriona Chief Development Officer | Akero Therapeutics, Inc. (AKRO) | 21-Sep-23 | Planned Option Sale | 4,383 | $48.07 | $210,696.00 | (9%) 51.01K to 46.63K | |
| 25-Sep-23 8:31 PM View: | Yale Catriona Chief Development Officer | Akero Therapeutics, Inc. (AKRO) | 21-Sep-23 | Sale (Planned) | 617 | $48.07 | $29,659.90 | (1%) 46.63K to 46.01K | |
| 23-May-23 9:55 PM View: | Graham G. Walmsley Director | Akero Therapeutics, Inc. (AKRO) | 19-Sep-23 | Purchase | 400,000 | $26.00 | $10,400,000.00 | 18450% 2.17K to 402.17K | |
| 25-Sep-23 8:31 PM View: | Yale Catriona Chief Development Officer | Akero Therapeutics, Inc. (AKRO) | 13-Sep-23 | Planned Private Option Sale | 617 | $50.34 | $31,059.80 | (1%) 46.63K to 46.01K | |
| 25-Sep-23 8:36 PM View: | Cheng Andrew President and CEO Director | Akero Therapeutics, Inc. (AKRO) | 13-Sep-23 | Private Sale (Planned) | 1,682 | $50.34 | $84,671.90 | (< 1%) 462.68K to 461.0K | |
| 25-Sep-23 8:30 PM View: | Rolph Timothy Chief Scientific Officer | Akero Therapeutics, Inc. (AKRO) | 13-Sep-23 | Private Sale (Planned) | 531 | $50.34 | $26,730.50 | (< 1%) 151.22K to 150.69K | |
| 25-Sep-23 8:28 PM View: | Young Jonathan Chief Operating Officer | Akero Therapeutics, Inc. (AKRO) | 13-Sep-23 | Private Sale (Planned) | 562 | $50.34 | $28,291.10 | (< 1%) 243.74K to 243.18K | |
| 25-Sep-23 8:31 PM View: | White William Richard Chief Financial Officer | Akero Therapeutics, Inc. (AKRO) | 13-Sep-23 | Private Sale (Planned) | 632 | $50.34 | $31,814.90 | (3%) 19.1K to 18.47K | |
| 18-Sep-23 6:48 PM View: | Cheng Andrew President and CEO Director | Akero Therapeutics, Inc. (AKRO) | 01-Sep-23 | Option Exercise | 25,000 | $6.36 | $159,000.00 | 5% 462.68K to 487.68K |
